SCHEMBL764438

SCHEMBL764438

CS(=O)(=O)N1CCN(c2ccc(Nc3ncc(C(N)=O)c(Nc4ccc5cn[nH]c5c4)n3)cc2)CC1

nearest known ligand 0.79

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SYK P43405 12/20 0.79
JAK1 P23458 3/20 0.67
JAK2 O60674 2/20 0.67
JAK3 P52333 2/20 0.67
EGFR P00533 1/20 0.61
FGFR1 P11362 1/20 0.61
BRD4 O60885 2/20 0.58
PDGFRB P09619 6/20 0.58
PDGFRA P16234 5/20 0.58
CHEK1 O14757 2/20 0.57
RET P07949 2/20 0.57
TYK2 P29597 2/20 0.57
FLT3 P36888 2/20 0.57
RPS6KA3 P51812 2/20 0.57
MAPK10 P53779 2/20 0.57
STK4 Q13043 2/20 0.57
STK3 Q13188 2/20 0.57
MARK2 Q7KZI7 2/20 0.57
TBK1 Q9UHD2 2/20 0.57
RPS6KA6 Q9UK32 2/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL736542 0.88 SYK (1.00) SYKEGFRFGFR1
SCHEMBL763394 0.88 SYK (0.87) SYKEGFRFGFR1PDGFRBPDGFRA
SCHEMBL764416 0.87 SYK (0.80) SYKEGFRFGFR1BRD4PDGFRB
SCHEMBL763498 0.87 SYK (0.80) SYKEGFRFGFR1PDGFRBPDGFRA
SCHEMBL15161209 0.83 SYK (0.67) SYKJAK1JAK3EGFRFGFR1
SCHEMBL8735645 0.83 SYK (0.79) SYKJAK1JAK2JAK3PDGFRB
SCHEMBL28638852 0.82 EGFR (0.77) SYKJAK2JAK3EGFRFGFR1
SCHEMBL764418 0.81 SYK (0.67) SYKJAK1JAK3EGFRFGFR1
SCHEMBL21554059 0.81 SYK (0.82) SYKJAK1JAK2JAK3BRD4
SCHEMBL737349 0.80 SYK (1.00) SYKJAK1JAK2JAK3PDGFRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8138339-B2 Inhibitors of protein kinases PORTOLA PHARMACEUTICALS, INC. (US) 2012-03-20 US disclosed
US-20090318407-A1 Inhibitors of protein kinases PORTOLA PHARMACEUTICALS, INC. (US) 2009-12-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090318407-A1 Inhibitors of protein kinases SYK, BTK, JAK1 SYK 1/4885JAK1 3/4885JAK2 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.